Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline Sells 1,740,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Matthew Gline sold 1,740,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $21.68, for a total transaction of $37,723,200.00. Following the completion of the sale, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at $374,864,977.60. This represents a 9.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Matthew Gline also recently made the following trade(s):

• On Thursday, September 18th, Matthew Gline purchased 3,315 shares of Roivant Sciences stock. The stock was bought at an average price of $15.07 per share, with a total value of $49,957.05.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $22.70 on Thursday. The firm has a market cap of $15.79 billion, a PE ratio of -40.54 and a beta of 1.22. The stock’s fifty day moving average price is $19.76 and its two-hundred day moving average price is $14.95. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $23.47.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Thursday. JPMorgan Chase & Co. increased their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Jefferies Financial Group raised their target price on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Finally, Citigroup boosted their price target on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $24.81.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of ROIV. PNC Financial Services Group Inc. boosted its stake in shares of Roivant Sciences by 44.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock valued at $103,000 after purchasing an additional 3,169 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Roivant Sciences by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company’s stock worth $28,733,000 after buying an additional 35,123 shares during the period. HighTower Advisors LLC grew its holdings in Roivant Sciences by 36.4% during the 1st quarter. HighTower Advisors LLC now owns 13,932 shares of the company’s stock worth $141,000 after acquiring an additional 3,719 shares during the last quarter. Russell Investments Group Ltd. increased its position in Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after acquiring an additional 2,233 shares during the period. Finally, Candriam S.C.A. bought a new position in shares of Roivant Sciences during the first quarter valued at $276,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.